In 2016, a study utilizing human lung cancer PCTS, autologous tumor antigen-specific TILs and peripheral blood T cells (PBTs) showed that CD103-expressing CD8+ T cells had the ability to infiltrate epithelial tumor islets, in contrast to CD103-negative CD8+ cells, which preferentially accumulated in the tumor stroma [37]. This evidence concerns the gene CD8A and lung cancer.